• Knightscope’s spring Robot Roadshow is set to kick off on April 12, and will cover key states in the U.S. before making it to the capital for National Police Week
• Knightscope plans to leverage the roadshow to forge direct connections with potential clients and strike up conversations in a compelling fashion
• The roadshow will cover as many major cities as possible for the 2022 calendar year

Studies have shown that 70% of individuals are converted into repeat paying clients once they attend an experiential marketing event. In addition, 85% of clients note that they are more likely to make a purchase after participating in such events (https://ibn.fm/K2rQL). Knightscope (NASDAQ: KSCP) is a leader in developing autonomous security technologies for the U.S. market. As such, it has announced its spring schedule for the Robot Roadshow, intending to grab potential clients’ attention, forge direct connections with them, and strike up conversations that would aid in pushing its technology and business forward (https://ibn.fm/knaLm). Dubbed “The Robot Roadshow,” this periodic event allows attendees to get a feel and more in-depth understanding of the technology that enables their autonomous security Robots (“ASRs”) to make sites safer today. Attendees interact directly with each robot and see the Knightscope Security Operations Center (“KSOC”) user interface in action. The company has three primary offerings: the K1 stationary machine, the K3 indoor machine, and the K5 outdoor machine. These ASRs autonomously patrol client sites with no remote control, offering a visible, force-multiplying, physical security presence that offers additional asset protection, crime deterrence, and monitoring changes. The crime-fighting robots tour will feature these three ASR models and will be hosted virtually by a Knightscope expert. The roadshow has, so far, made 35 landings in 10 different states, and the spring line-up will kick off on April 12, 2022, in the Midwest. The tour is currently scheduled to hit Minnesota, Illinois, Wisconsin, Ohio, and Indiana, before making its way to Washington, just in time to celebrate National Police Week. The plan for the Robot Roadshow is to cover as many major cities as possible for the 2022 calendar year. Knightscope is confident that with these roadshows, it will attract new clients and retain existing ones, ultimately creating value for its shareholders. You can view a video of a previous Robot Roadshow hosted by the Los Angeles Police Department at https://ibn.fm/J5H44 For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com, and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Cepton continues to be at forefront of state-of-the-art engineering science; sponsors The AutoDrive Challenge(TM) II and serves as an exclusive LiDAR supplier
• During this competition, faculty members and students from ten North American universities will spend four years developing autonomous vehicles that require no human interaction in their operations
• Participating teams will work with directional lidars for the first time as academic community recognizes Cepton lidars for their exceptional combination of performance, reliability, and embeddability

As a leading innovator in the LiDAR space, Cepton (NASDAQ: CPTN) has always been committed to becoming the bridge between cutting-edge science and the automotive industry. Autonomous driving and its great enabler – LiDAR technology – are ready to take over mobility space, as the innovative technology makes strides in terms of decreasing costs and improving commercialization potential. Cepton appears determined to be a visible part of that landscape, as it becomes a sponsor and an exclusive LiDAR provider for ten universities in North America gathered in a four-year STEM education program called The AutoDrive Challenge(TM) II (https://ibn.fm/283iq). A result of the partnership between GM and SAE, The AutoDrive Challenge(TM) is designed to advance STEM education and contribute to the ground-breaking work within the autonomous driving space. Participating academic institutions include Kettering University, Michigan Technological University, North Carolina A&T State University, Pennsylvania State University-University Park, Queen’s University, Texas A&M University, The Ohio State University, University of Toronto, University of Wisconsin-Madison, and Virginia Polytechnic Institute and State University. During the program, faculty members and students will develop autonomous vehicles that can navigate urban driving courses following SAE’s Level 4 of driving automation, which means that vehicles do not require human interaction in their operations. The vehicles will be tested in Mcity, the world’s first purpose-built ground for testing the performance and safety of automated vehicles, which is used by many leading automotive OEMs trial smart mobility projects. To achieve a high level of security, participating teams will need to equip their vehicles with advanced perception capabilities, for which LiDAR technology is expected to play a critical role. This is where Cepton steps in. The Company will provide high-performance LiDAR solutions to the teams to enable their integrated systems. The AutoDrive Challenge(TM) II proves that LiDAR is becoming increasingly present in the autonomous driving space. “We felt this program offered us a fantastic opportunity to help advance the LiDAR education in both the automotive industry and academia,” said Dr. Jun Pei, CEO of Cepton. “LiDAR is going mainstream with it being deployed in advanced driver assistance systems (‘ADAS’) in everyday consumer vehicles to be available in the next few years. This sensor technology is not only capable of improving vehicle safety but also critical in enabling higher levels of autonomy. We are dedicated to helping proliferate the benefits of LiDAR technology by focusing on increasing its mass-market scalability with our proprietary Micro Motion Technology (MMT(R)), which is designed to enable an optimal balance between performance, reliability, and affordability. While we look forward to working with all the participants to help enhance their AV projects with LiDAR perception, we are also excited to learn from the experience working with such an intellectual community,” he concluded. The future for self-driving vehicles and their enabling technologies such as LiDAR systems seem bright. With improved safety levels of autonomous vehicles, the number of human drivers is expected to decrease gradually. Some projections go as far as to predict that human driving is on its way to soon becoming the thing of the past. IDTechEx, a market research firm focused on emerging technologies, believes that the safety level of autonomous vehicles will reach or even surpass that of human drivers in 2024, leading to a potential ban of human drivers on public roads by 2050 (https://ibn.fm/QH8Dn). Although this may be a bold prediction, the world appears to be on the brink of a new era in autonomous driving – and LiDAR technology has an opportunity to become a big part of that disruption. This innovative technology has been catching up to optical cameras – its main competing technology – and will take over if the advancements in optical cameras fail to measure up. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Chase Edgelow and the EverGen Infrastructure team has sought to cater to the rapidly rising demand for carbon-free energy sources through a focus on renewable natural gas (“RNG”)
• Current forecasts suggest that as much as 10% of North America’s natural gas demand could be satisfied by RNG in the coming future
• EverGen is planning to expand their production footprint, recently signing a letter of intent to acquire a stake in an agricultural project in Alberta wherein biodegradable waste will be converted into RNG and sold to FortisBC
• RNG proponents increasingly believe that the fuel source could eventually play a role in targeting two of society’s most pressing issues – the world’s growing waste production as well as its mission to achieve a carbon neutral future

The world produces over 2.12 billion tons of waste per annum; To put that figure into perspective, if all the waste was put on trucks, it would circle around the world 24 times (https://ibn.fm/UJnsY). For Chase Edgelow, that is an opportunity. The CEO and Founder of British Columbia-based EverGen Infrastructure (TSX.V: EVGN) (OTCQB: EVGIF) is creating a cutting edge renewable energy company, focused around converting organic waste into renewable natural gas (“RNG”), a non-fossil fuel form of natural gas. With governments the world over pledging to pursue a carbon neutral future in the coming years, RNG stands to play a significant role in the decarbonization of North America’s gas supply going forward. Forecasts suggest that as much as 10% of the continent’s natural gas demand could be satisfied by RNG in the not-too-distant future. Nowhere is that phenomenon more evident than within the utilities sector. Canada’s Enbridge Gas Inc, North America’s largest natural gas utility by volume, has already begun to work towards this goal, recently announcing a partnership to design and build eight new RNG project sites across the United States (https://ibn.fm/z7qeZ) and construct seven large-scale Canadian RNG projects with an additional 50+ projects in various stages of development; all whilst simultaneously breaking ground on what is soon set to be Ontario’s largest RNG facility by Niagara Falls (https://ibn.fm/hd2iE). EverGen Infrastructure Corp caters to the burgeoning RNG market, most recently through the signing of a letter of intent for the acquisition of a 67% interest in a biogas facility in Alberta. The facility, which will be centred around the currently operating Perry Family Farm, will seek to convert biodegradable agricultural waste into biogas which will subsequently be upgraded to RNG for use in the gas grid. The facility has an offtake agreement with FortisBC, with the supplied RNG contributing to FortisBC’s target to source at least 15% of its gas supply from carbon neutral sources by 2030 (https://ibn.fm/7g2fF). “We are thrilled to be partnering with GrowTEC and working with the Perry Family Farm on EverGen’s first project in the Alberta market. Alberta is a region with high quality organic feedstock and represents a strategic market for EverGen as it plans to become a dominant RNG producer in the province,” said Chase Edgelow, CEO of EverGen. EverGen manages two organic waste processing facilities in British Columbia in addition to Fraser Valley Biogas, Western Canada’s first RNG facility which has been in production since 2011. The Net Zero Waste compost facility in Abbotsford will be expanding this year with construction of an Anaerobic Digester facility that will use blended feedstock from agricultural, municipal, and commercial organic waste to produce RNG that will feed into FortisBC’s gas network under a long-term contract. The Sea to Sky Soils facility near Pemberton, BC plans to grow its waste processing capacity by approximately 50% and has future RNG potential as well. The company has plans to further its geographic footprint, and is evaluating several RNG projects in Alberta, Ontario, and Quebec. Organic waste derived from food production, food waste, farming, landfill, and wastewater treatment are said to be responsible for up to 25 percent of human-caused global emissions of methane, a harmful greenhouse gas. Chase Edgelow and other RNG advocates the world over believe that they can, rather uniquely, address two critical issues through the production of renewable natural gas, namely – how to tackle the world’s increasing waste production whilst simultaneously, targeting cleaner, renewable energy sources (https://ibn.fm/6PCtJ). “We need to deal with our waste, as humans,” [Edgelow] stated. “We need waste infrastructure. But we also want to decrease carbon emissions. So why would we let the energy from that waste infrastructure go straight into the atmosphere and go to waste?” For more information about EverGen Infrastructure Corp. and its projects, visit the company’s website at www.EvergenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• Hollywall Entertainment Inc. currently has a market cap of $73.53 million, attributed mainly to its leveraging of developing technologies
• The company, through HW Vision, a wholly-owned subsidiary, is pushing 5G and banking on its adoption over the coming years, projected to drive a 52% growth in the 5G services market by 2030
• Hollywall is also exploring new ways to create digital equity as it seeks to address the digital divide
• Through its investment in 5G, Big Data, and AI, Hollywall is not only growing its digital marketplace presence but also driving value for its shareholders

Hollywall Entertainment (OTC: HWAL) has positioned itself as a telecommunication, media, infrastructure, technology, broadcasting, and entertainment company. Through its budding list of subsidiaries, the company has achieved a market cap of $73.53 million as of March 2022. For a company founded in 2009, its growth has been incredible and has been primarily attributed to its identification and capturing of high-growth technologies (https://ibn.fm/v7PkQ). Hollywall is focused on the potential of the digital marketplace, pushing its investment in this sector. Through its wholly-owned subsidiary, HW Vision, the company offers state-of-the-art services, tapping into industries such as video broadcasting, managed internet services, domain hosting, telehealth services, and, most importantly, 5G and fiber network installation services. In 2021, the 5G services market size was valued at $47.3 billion. Furthermore, it is projected that by 2030, this sector will post a CAGR of 52% over the forecast period (2022-2030), driven mainly by the growing demand for high-speed data connectivity for unified Internet of Things (“IoT”) applications (https://ibn.fm/IHmb4). The North American market is projected to post the highest growth in 5G adoption over this period, mainly stemming from the proliferation of the internet, along with 5G’s potential to help realize transformation in various industry verticals. Hollywall is confident that the 5G sector alone has the potential to generate significant interest and market opportunities for the company going forward. Its management also reckons that this industry’s growth will be further complemented by the company’s community-focused initiatives, including but not limited to the development of smart cities. Even as the company explores other new avenues of revenue and value creation for its shareholders, it continues to bank on 5G technology as one of the key pillars that will define its growth as time progresses. Recently, the company announced its venture into music NFTs with the formation of a new research and development (“R&D”) division that would also explore cryptocurrency technologies, blockchain, and token omics (https://ibn.fm/pLVmA). Hollywall is also exploring new ways and methods of creating digital equity to address the so-called digital divide between the quality internet haves and have-nots. This has seen the launch of its “Fiber to the People” program, a campaign that acknowledges how the digital divide disproportionately affects the elderly, those living in rural areas and in poverty, as well as the homeless. Its management believes that 5G will be integral to solving this problem and improving society overall (https://ibn.fm/y9DTo). Hollywall is no stranger to pushing the envelope, sparking conversations, and innovating, particularly when it comes to technology and offering access to the internet. With its growing portfolio of products and service offerings, the company proves that 5G, Big Data, and Artificial Intelligence (“AI”) are the future. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

Entrepreneurs, businesses, and enthusiasts of the modern finance, fintech, and digital assets niche are invited to attend the Paris Blockchain Week Summit being held at none other than the iconic Palais Brongniart. As an extension of the event, the PBWS will include the Paris NFT day on 12 April, to educate and spread awareness about NFT trading. Paris NFT Day Join in for an interactive session on NFTs and Web 3 ecosystem at the Paris NFT Day on 12 April. The conferences will offer a clear understanding of the projects and businesses that are underway in this niche and the key players in the field. This platform offers immense opportunities for new players to network and discover investors for their innovative projects. Showcase your business ideas and talents to gain visibility on this forum where industry thinkers and leaders of the NFT space will make their presence felt. Learn about the new projects on Metaverse, Gaming, Fashion & Luxury, Sports & Athletes, the Arts, and discover the new opportunities that these applications have to offer. The event will feature 2,000+ attendees, 50+ sponsors and 100+ media partners, along with 100+ speakers throwing light on important aspects of the NFT and Web3 space. Paris Blockchain Week Summit Witness a larger-than-life event at the Paris Blockchain Week Summit, a flagship event of the Paris Blockchain Week, showcasing 3,000 attendees, 70 sponsors, 250 speakers and 100 media partners. ‍Meet and connect with the influencers, regulators, and leaders of the digital assets arena. The two-day event will cover a wide spectrum of topics in the blockchain and digital asset space. The conferences will host discussions and talks on the journey, innovation, market insights and what the future holds for this ever-growing modern finance sector. Meet the brightest minds and game-changers of the industry who will guide, share valuable insights and walk you through the experience of the unlimited scope and prospects of ushering into the new era of digital finance. Both the events will be held at the Palais Brogniart, a landmark in Paris that served as the French Stock Exchange for nearly 200 years. It is the perfect venue to welcome new financial opportunities and with the huge space, the building offers, it is a perfect venue to accommodate the large crowd of people attending the events. For more information, please visit https://www.nftday.paris & https://pbwsummit.com.

The Microdose Plant Medicine Week will be held on April 5-8th 2022, at the Mediterranean Conference Centre, one of the finest heritage buildings of Valletta, Malta. The Centre is a landmark venue having membership of the prestigious Historic Conference Centres of Europe (“HCCE”). Investors, entrepreneurs, psychedelic and cannabis researchers, policymakers, and professionals from the health, legislation, and education fields are invited to attend the event. The agenda of the event focuses on the expansion of cannabis and psychedelic medicine usage and trade on the island and reviewing the existing laws and schemes to encourage cannabis investment opportunities in Malta. Knowledge and information sharing will be done through case studies, presentations, discussions, keynotes, and insights from industry leaders, researchers, and experts about the potential and scope of investments in the psychedelic sector. The Plant Medicine Week is well-curated by an expert team of professionals who have hosted numerous conferences in the cannabis and psychedelic medicine sector. They have partnered with the best hotels in the region to offer a comfortable stay to the attendees. This event is organized in two sections:

• Cannabis Medicine – organized by – Medcann World Forum (April 5-6th 2022)-Influential industry leaders from Europe and all across the globe come together for a cannabis discussion on legislation, business, regulatory, education & research. They will further share insights on how new cannabis ventures and investments can find their way to Europe and the barriers of entry in Germany.
• Psychedelic Medicine – (April 7-8th 2022)- organized by Microdose Psychedelic Insights a leading media company focused on organizing events on psychedelic medicine. Microdose hosts this conference to explore the immense scope of psychedelic investment, the laws.

The Plant Medicine Week opens novel opportunities in the psychedelic investment sector for traders in and around the island. The event will feature discussions on the latest innovations in drug development, the laws and regulations that effect cannabis trade, public interest, and business trends that impact the support of laws surrounding cannabis use and trading. Tickets are available for either one or both of the events. Participants from all over the globe can also access the conference virtually. To learn more, please visit https://plantmedicineweek.com/.

• Lexaria is a global innovator that has developed the patented DehydraTECH(TM) technology that improves bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”)
• The company strategically partners with third-party organizations seeking to explore formulation opportunities with their specific APIs
• Lexaria is evaluating the effectiveness of various DehydraTECH-processed APIs, including CBD, nicotine, sildenafil, and more
• According to company CEO Chris Bunka, the management team is positioning the company to ensure that it has multiple paths to success

In pursuit of multiple paths to success, Lexaria Bioscience (NASDAQ: LEXX), developer of the patented DehydraTECH(TM) drug delivery platform, strategically partners with third-party companies looking to explore formulation opportunities with their targeted APIs, out-licenses its technology, and is actively developing lead product candidates. According to a 2021 video, the company also hopes to provide a lifeline to pharmaceutical companies noting that DehydraTECH(TM) “may provide additional patent extensions for existing drugs, which is a potential billion-dollar insurance policy to original drug manufacturers” (https://ibn.fm/qItAF). So named because it features a dehydration synthesis procedure, the DehydraTECH technology has been found to improve bioavailability, speed of onset, and brain absorption of active pharmaceutical ingredients (“APIs”). To discover more about the effectiveness of DehydraTECH, Lexaria has studied the DehydraTECH processing of various APIs, most recently the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil – whose most widely known product available for sale is Viagra(R) – for potential application in the management of erectile dysfunction. The animal study revealed that DehydraTECH resulted in faster and higher overall delivery of sildenafil into the bloodstream (https://ibn.fm/VYdtO) than concentration-matched controls. Valued at $4.99 billion in 2021, the erectile dysfunction drug market is expected to grow at a CAGR of about 4.6% between 2021 and 2025, reaching $5.97 billion (https://ibn.fm/pRAKd). Other DehydraTECH markets being evaluated by Lexaria include the broader cannabidiol (“CBD”) market, which is projected to grow at a 51% CAGR from a value of $2.7 billion in 2021 to approximately $111 billion by 2030 (https://ibn.fm/eLpuv). CBD is increasingly used in a myriad of applications that Lexaria is equally targeting. The company recently announced it had begun the first phase of its epilepsy animal research to evaluate the seizure-inhibiting activity of DehydraTECH-CBD compared to Epidiolex(R), the sole FDA-approved CBD-based seizure drug (https://ibn.fm/Q6rLN). The global epilepsy market, valued at $10.3 billion in 2020 and 10.6 billion in 2021, is projected to grow to $12.9 billion in 2026 and $16.6 billion by 2031 (https://ibn.fm/qUPGW). In addition, Lexaria is evaluating DehydraTECH-CBD as a potential treatment for hypertension, announcing late last year it had received an Independent Review Board (“IRB”) approval ahead of schedule for its fourth DehydraTECH-CBD human hypertension study, HYPER-H21-4, tentatively set to begin this month (https://ibn.fm/0VRcd). HYPER-H21-4 will build on previous human and animal research, which demonstrated that DehydraTECH-processed CBD results in a rapid and sustained drop in blood pressure and reduces arterial stiffness. The World Health Organization reports that an estimated 1.28 billion aged between 30 and 79 years have hypertension. But, of concern, only about 1 in 5 persons have it under control (https://ibn.fm/zDYwM). DehydraTECH-CBD could therefore provide patients the much-needed reprieve, enabling Lexaria to also tap into the global hypertension drugs market expected to grow at a CAGR of 3.4% from a value of $24.4 billion in 2020 to $31.5 billion by 2028 (https://ibn.fm/HdOkS). Lexaria has also evidenced faster and more effective delivery of DehydraTECH-processed nicotine. Results from an animal study, the NIC-A21-1, announced last fall, showed that DehydraTECH-oral nicotine peaked in the bloodstream 10x to 20x faster than controls. At the same time, the peak levels achieved were up to 10x higher than controls. Valued at $59.8 billion in 2021, the global nicotine replacement therapy market is expected to reach $147.9 billion by 2028, growing at a 16.3% CAGR (https://ibn.fm/gAxgQ). “We are currently pursuing or investigating several large market opportunities, the smallest of which is currently generating over $1 billion in annual revenue. In many of these markets, growth is expected to be significant over the next several years. The Lexaria management team is trying to ensure that we have multiple paths to success: if any one single area of investigation were to fail, we want to ensure we still have other opportunities to exploit,” wrote Lexaria CEO Chris Bunka in an annual letter to stakeholders (https://ibn.fm/VLw0X). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• LiDARs have been one of key enablers for autonomous vehicle sector, but this unique technology offers use cases beyond automotive industry
• Consumer Electronics Show, one of the world’s most influential tech events, demonstrates that LiDAR is growing within non-automotive landscape, including smart city/infrastructure and security
• Cepton set to benefit as the Company has already established its presence in non-automotive, delivering LiDAR systems for smart cities, spaces, and industrial applications around the globe

Cepton (NASDAQ: CPTN), a Silicon Valley leader in innovative, high-performance LiDAR solutions, appears well-positioned to benefit as the non-automotive applications of the LiDAR technology grow. LiDAR technology seems to be on its path to move away from the realm of sci-fi-like promises toward real applications and commercialization. While the autonomous vehicle sector strives to make strides in terms of a safe and sustainable driving experience, for which LiDARs are one of the key enablers, the question remains as to what the future holds for this technology beyond the automotive sector? If the latest Consumer Electronics Show (“CES”) is anything to go by – and it should be, as the event prides itself on being the most influential tech happening in the world – LiDAR has grown in importance not only for the automotive sector but also for non-automotive applications. The latter includes smart city/infrastructure and security, which are becoming increasingly important for LiDAR producers. These applications require top-notch 3D image processing and actionable perception software, where LiDARs can shine (https://ibn.fm/BblKI). As a pioneer in the LiDAR space, Cepton has already been riding the rising non-automotive wave, collaborating with global partners to transform transportation infrastructure, public venues, and large commercial facilities using innovative LiDAR solutions. For example, in 2020, the Company partnered with The Indoor Lab in a pilot project at an Orlando International Airport terminal. The aim of the project was to deliver anonymous footfall tracking through a LiDAR-based crowd analytics solution to assist travelers in avoiding crowded areas and maintenance crews in targeted cleaning (https://ibn.fm/dPcPB). In addition, last year, Cepton joined the Qualcomm Smart Cities Accelerator Program in a bid to advance the future of smart infrastructure with their LiDAR systems. And most recently, Cepton engaged in developing a LiDAR-based vehicle detection system to help build city-wide smart transportation infrastructure in South Africa’s Cape Town which will provide authorities with analytics designed to improve traffic flow and safety for drivers and pedestrians (https://ibn.fm/cBk7D). With a product portfolio diversified across both automotive and non-automotive spaces, Cepton seems to be well-positioned to leverage a variety of intelligent sensing applications in markets outside of automotive. As the Company continues to employ its proprietary solutions designed to provide accurate, real-time, and anonymized 3D perception, it appears poised to make its footprint in the global landscape to transform smart cities, spaces, and industrial applications. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential
• InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products
• The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year
• The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions, including glaucoma and a severe genetic skin disorder known as epidermolysis bullosa (“EB”)

Rare cannabinoid drug developer InMed Pharmaceuticals (NASDAQ: INM) is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year to better approach the pharmaceutical and health and wellness markets (https://ibn.fm/9B9dG). InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (“CBC”) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (“CBT”) to the health and wellness market on a B2B basis according to a company news release, so revenues from those sales would appear in future quarterly reports (https://ibn.fm/feLVe). The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates sales of cannabidivarin (“CBDV”) and tetrahydrocannabivarin (“THCV”) in the coming months as its next revenue generators. A Harvard Medical School report noted THCV has some “exciting” potential in treating obesity and diabetes because of its apparent capacity to reduce fasting insulin levels, enhancing weight loss and improving glycemic control, which has been demonstrated in animal trials but is without human studies to support it thus far (https://ibn.fm/MQbIs). CBDV is being considered as a potential means of modulating “brain excitatory-inhibitory systems” — including its possibilities for treating the irritability in autistic children (https://ibn.fm/rEyIq). “We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand,” BayMedica SVP and General Manager Shane Johnson stated in January (https://ibn.fm/d92LZ). “By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large scale supplier of high quality rare cannabinoids in these sectors.” The company expects to produce more than 100 kilograms of CBDV and THCV under the initiative. Because of the very limited quantities of rare cannabinoids that make them effectively impractical from an economic standpoint to extract directly from the plant for pharmaceutical use, InMed’s R&D operation is working to develop synthetic formulations for the treatment of specific conditions. INM-755, a cannabinol (“CBN”) topical cream under clinical development for the treatment of a severe genetic skin disorder known as epidermolysis bullosa (“EB”), is undergoing patient screening and treatment in a Phase 2 clinical trial at 13 sites in eight European countries following two Phase 1 clinical trials in healthy volunteers. The company reports it is the first time a CBN-based formulation has ever advanced to a Phase 2 clinical trial (https://ibn.fm/WAefY). InMed is also developing a CBN formulation for the potential treatment of glaucoma. INM-088 dosing is currently being researched for topical delivery to the eye as a means of reducing intraocular pressure and providing neuroprotection of the eye. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• InnerScope Hearing Technologies recently announced that subsidiary HearingAssist’s products would be carried by RiteAid.com
• The distribution agreement with one of the nation’s leading drug store chains comes as InnerScope seeks to position itself to benefit from the upcoming OTC Hearing Aid Law
• The Hearing Aid Law will create a new category of hearing aids, available from any retailer without need of doctor appointments or fittings.
• The law will also see the average cost of these hearing aids decline significantly relative to their current cost – allowing for greater access from the over 40 million Americans unable to afford the product

InnerScope Hearing Technologies (OTC: INND), a disruptive manufacturer and distributor/retailer of direct-to-consumer and FDA registered Bluetooth-controlled hearing aids and personal sound amplifier products (“PSAPs”), recently announced that subsidiary HearingAssist would be launching its branded hearing products and related supplies on RiteAid.com. The announcement will mark yet another milestone for HearingAssist, a long-established leader in the direct-to-consumer hearing aid market, with the company having sold over 500,000 hearing aids since 2008 and generated upwards of over $72 million in top-line revenues from 2018 to 2021 whilst simultaneously transforming into Walmart’s largest hearing aid supplier in the process (https://ibn.fm/Bnm1E). In October 2021, the FDA proposed its initial guidelines for the ground-breaking Over-The-Counter (“OTC”) Hearing Aid Law (“OTC Hearing Aid Law”); will see a new category of hearing aids created, which will be available from any seller without doctor appointments or fittings, and sold at a fraction of the typical cost – about $600 per pair instead of the average $5,000 (which includes fittings and follow-up services) (https://ibn.fm/JNgHY). In anticipation of the upcoming OTC Hearing Aid Law, the management teams at HearingAssist and InnerScope have sought to forge relationships with major retailers and pharmacy chains, seeking to establish and promote its product portfolio ahead of a potential roll-out across their partners’ in-store locations and websites. The successful placement of HearingAssist products on RiteAid.com, one of the nation’s largest drugstore chains with stores in 17 states across the United States, is an early affirmation of the company’s ongoing strategy – one which has already seen the company roll-out its products across their www.iHearDirect.com e-commerce website as well as on the likes of FSAStore.com, HSAStore.com, and WellDeservedHealth.com. “The management teams of HearingAssist and InnerScope are proud to offer HearingAssist Products for all Rite Aid customers,” stated Matthew Moore, President and CEO of InnerScope Hearing Technologies. “The launch of HearingAssist Products on RiteAid.com increases InnerScope’s and HearingAssist’s market penetration and brand recognition ahead of the OTC Hearing Aid Law” (https://ibn.fm/NiXVt). The RiteAid.com win follows on the heels of a number of operational highlights achieved by the company in recent months. In early October, InnerScope announced that it had acquired iHEAR Medical Inc, a direct-to-consumer hearing solutions provider, providing InnerScope with access to over 40 patents and an FDA-registered manufacturing and R&D facility in the process. The company subsequently presented its preliminary fourth quarter 2021 results, with revenues of $633,894 for the year’s final three months (https://ibn.fm/hBIRI) – a record result that coincided with InnerScope’s HearingAssist receiving purchase orders from Walmart of nearly $280,000. (https://ibn.fm/3WoOY). A recent White House fact sheet revealed that the elevated cost of hearing aids permitted a mere 14% of the approximately 48 million Americans with hearing loss to afford the life-changing product (https://ibn.fm/pEwQI). A heavily concentrated marketplace – with the four largest hearing aid manufacturers controlling upwards of 84% of the market – has also contributed to the elevated pricing for the devices. Now and with the forthcoming OTC Hearing Aid Law set to disrupt the decades-long status quo for the hearing aids market, InnerScope will seek to leverage upon its hugely disruptive, direct-to-consumer model to revolutionize the hearing aid market once and for all. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.iHearDirect.com NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND